Healthcare Industry Insights: June 2019

Thursday, 27 June 2019

Epilepsy Drugs Market - Segmentation and Growth Opportunities, 2024

The global Epilepsy Drugs Market is expected to reach over USD 5,474.14 million by 2024, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.
Global Epilepsy Drugs Market

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/epilepsy-drugs-market

Further key findings from the study suggest:

The second generation anti-epileptic drug class is estimated to have over 30% market share in 2015 owing to the high prescription rates, improved tolerability, and increased efficacy due to the novel mechanisms of action of these drugs
The third generation anti-epileptic drug class is expected to witness the fastest growth with a CAGR of over 4% over the forecast period. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
The growing need to improve the efficacy of the existent drugs and the need to develop new and enhanced anti-epileptic drugs to minimize the associated side-effects, such as dizziness, fatigue, weight gain, and depression are the propelling factors expected to drive the market growth over the forecast period
North America dominated the market in terms of revenue with over USD 2,000 million in 2015 owing to the presence of well-established healthcare infrastructure, favorable government initiatives directed at the betterment of the healthcare system, and the presence of extensive research and development activities
Asia Pacific is expected to witness lucrative growth with a CAGR of around 4.5% over the forecast period owing to the rising disposable income levels and the favorable, healthcare government initiatives in emerging economies, such as India, Japan, and China
Some major players of the epilepsy drugs market include UCB Pharma Ltd., Sanofi S.A, Valeant Pharmaceuticals International, Inc., Pfizer, Inc., Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Inc., Novartis AG, GlaxoSmithKline PLC., Sunovion Pharmaceuticals, Inc., and Cephalon, Inc.
Most of the key players are engaged in strengthening their product portfolio to increase their market share. The introduction of novel drugs is expected to foster the market penetration of anti-epileptic drugs. For instance, in August 2015, the FDA-approved epilepsy tablet, Aptiomby Sunovion Pharmaceuticals, Inc. for people suffering from partial-onset seizures.

Grand View Research has segmented the global epilepsy drugs market on the basis of treatment and region:

Global Epilepsy Drug market (Revenue, USD Million, 2013 - 2024)

First generation anti-epileptic drug
Second generation anti-epileptic drug
Third generation anti-epileptic drug

Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2013 - 2024)

North America

U.S.
Canada

Europe

UK
Germany

Asia Pacific

India
China

Latin America

Brazil

South Africa

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/

Healthcare Reimbursement Market Analysis and Trends, 2026

The global Healthcare Reimbursement Market size is expected to reach USD 20.45 trillion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 19.0% during the forecast period. Supportive government initiatives along with rising cost of prescription medicines are likely to work in favor of the market.

The U.S. Affordable Care Act focuses on controlling and minimizing costs of healthcare. The law supports innovative methods to deliver medical care to reduce healthcare costs and makes affordable health insurance available to more people. Since the Obamacare came into effect in 2014, the number of uninsured children under the age of 18 in the U.S. reduced to 5.0% in 2015 as compared to 9% in 2008.

In addition, the Centre for Medicare & Medicaid Services is working towards delivery of reliable high-quality care, endorsement of efficient results in healthcare system, and making health insurance affordable for millions of Americans who are seeking and getting coverage. The Medicaid spending in the U.S. grew by 3.9% in 2016 or 17.0% of the total National Health Expenditure. And Medicare spending grew by 3.6% in 2016 or 20.0% of the total National Health Expenditure.

The underpaid segment is anticipated to dominate the market through 2026 owing to growing cases of frauds against government healthcare programs and increasing use of healthcare services that are not medically required. There have been several cases where businesses and individuals have defrauded federal and state government healthcare programs by submitting false claims for healthcare services, treatment, pharmaceutical, and medical devices that were never rendered.
U.S. healthcare reimbursement market

Also, the rivalry among healthcare providers and rising pressure from commercial and public payers to reduce costs as well as to improve care are shifting their focus towards value-based care models from volume-based healthcare models.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/healthcare-reimbursement-market

Further Key Findings from the Report Suggest:

Underpaid emerged as the largest segment in 2017 owing to increasing number of insurance plans that do not cover full reimbursement
On the basis of payers, private players accounted for the leading share in the market in 2017 owing to presence of a large number of private players
North America dominated the market in 2017. A raft of insurance players and strong reimbursement framework are facilitating the dominance of the region
The market in Asia Pacific is projected to witness rapid growth during the forecast period owing to rising penetration of insurance services in rural and urban areas
Some of the market players are UnitedHealth Group, Allianz, Aviva, Aetna, Nippon Life Insurance, CVS Health, WellCare Health Plans, BNP Paribas, The Blue Cross Blue Shield Association, and AgileHealthInsurance.

Grand View Research has segmented the global healthcare reimbursement market based on claim, payers, service provider, and region:

Healthcare Reimbursement Claim Outlook (Revenue, USD Million, 2014 - 2026)

Underpaid
Full Paid

Healthcare Reimbursement Payers Outlook (Revenue, USD Million, 2014 - 2026)

Private Payers
Public Payers

Healthcare Reimbursement Service Providers Outlook (Revenue, USD Million, 2014 - 2026)

Physician office
Hospitals
Diagnostic Laboratories
Others

Healthcare Reimbursement Regional Outlook (Revenue, USD Million, 2014 - 2026)

North America

U.S.
Canada

Europe

U.K.
Germany

Asia Pacific

India
China

Latin America

Brazil
Mexico

Middle East & Africa

South Africa
Saudi Arabia

Tuesday, 25 June 2019

Weight Management Market is Anticipated to Register 8.3% CAGR till 2025

The global Weight Management Market is expected to reach USD 442.3 billion by 2025, according to a new report by Grand View Research, Inc. Rising number of overweight and obese population coupled with rising popularity of various commercially available solutions is fueling the growth.

Increasing initiatives undertaken by market players in collaboration with the government to raise awareness about the adverse impact on health due to obesity are further anticipated to drive the market demand. The overweight and obese population are more prone to chronic diseases including diabetes, hypertension, and orthopedic diseases. Thus, rising awareness about weight management techniques is driving the market growth.

Thanks to westernization and urbanization, there is an increasing preference toward processed food as an alternative to home-cooked food. The increase in number of nuclear families coupled with a rise in the working population have fueled the demand for easily accessible & inexpensive fast food and takeaway meals. According to Statista, in 2015, revenue of fast food industry in the U.S was 203.2 billion. A hectic schedule coupled with increasing stress are resulting in higher intake of outside and takeaway food. This trend is anticipated to trigger the market growth.

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/weight-management-market

Further Key Findings From the Study Suggest:

The growing prevalence of obesity primarily due to sedentary lifestyle and lesser physical activities is augmenting market growth
The rising awareness of available solutions for weight loss and management is driving the growth
In diet, the beverage segment holds the largest share owing to increasing consciousness amongst people about their eating habits and adoption of general & personalized diet plans for better metabolism and losing the extra weight. Whereas, rising popularity of supplements, shake mix, tablets, and capsules are projected to grow over the forecast period
Fitness equipment such as cardiovascular training, strength building, and other equipment used in maintaining the weight account for the largest share in weight management
Increasing R&D for developing minimally invasive and noninvasive equipment are anticipated to increase the usage of surgical equipment over the forecast period
The fitness center services segment held the largest share of market, however with digitalization, online weight loss services are anticipated to grow over the forecast period
In 2016, North America dominated the global market with the largest revenue share of over 46.0%, due to the rising overweight population and commercial availability of minimally invasive procedures and noninvasive equipment
Asia Pacific is expected to emerge as the fastest growing region during the forecast period, primarily due to growing awareness about the importance of losing & management of extra weight in order to avoid adverse health effects coupled with improving healthcare infrastructure and emerging medical tourism
Some of the major players are Herbalife International, Inc.; NutriSystem, Inc.; Weight Watchers International, Inc.; eDiets.com; BRUNSWICK CORPORATION; Ethicon US, LLC; and GOLD'S GYM

Monday, 24 June 2019

Oligonucleotide Synthesis Market is Likely to Exhibit 12.4% CAGR till 2025

The global Oligonucleotide Synthesis Market size is expected to reach USD 3.9 billion by 2025 at a 12.4% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Continuous rise in usage of oligonucleotide synthesis across various aspects of human health management, from molecular diagnostics to therapeutics, is spurring revenue growth.

The recent success of oligonucleotide-based drugs in medicine due to increase in number of FDA-approved products is anticipated to boost revenue generation in this market. As of September 2017, there are six approved oligonucleotide therapeutic products.

A substantial number of oligos are being investigated for their usage in targeting various infectious diseases. For instance, dsDNA thioaptamers are reported to target the ribonuclease H (RNase H) domain of HIV-RT and are demonstrated to inhibit HIV-RT when used in vitro.

Brazil oligonucleotide synthesis market

In addition, demand for cancer-related thioapatmers that can detect presence as well as target tumor growth factors, such as TGF-β, is on a continuous rise. This, in turn, has led to increase in investments for exploring the significance of custom oligonucleotide synthesis in cancer research.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/oligonucleotide-synthesis-market

Further key findings from the report suggest:

Growing usage of ready as well as custom oligos in genomic research is expected to drive the market
Column-based oligos have a higher per nucleotide base price compared to array-based oligos. As a result, column-based oligos accounted for the largest revenue share by product type in 2017
North America dominated the global market in 2017 as a result of large investments in genetic research and effective regulatory policies that encourage gene-based research activities in the region
Asian countries are expected to emerge as a key source of lucrative revenue generation during the forecast period. This is primarily due to growing awareness as well as popularity of genetic medicine among the population
The market is highly fragmented, with the presence of several major and emerging players offering DNAs, RNAs, and other oligos. Market competition is anticipated to increase with growing number of new entrants offering customized services
Some of the key companies in the market are BioAutomation; Integrated DNA Technologies, Inc.; LGC Biosearch Technologies; Agilent Technologies; GE Healthcare Dharmacon Inc.; and Gene Scripts.

Grand View Research has segmented the global oligonucleotide synthesis market on the basis of product, application, end use, and region:
Oligonucleotide Synthesis Product Outlook (Revenue, USD Million, 2014 - 2025)

Oligonucleotides
- Oligonucleotides, By Product Type

- - Column-based Oligos
  - Array-based Oligos
- Oligonucleotides, By Nucleic Acid Type
  - DNA
  - RNA
Equipment
Reagents
Services
- Oligo Synthesis
  - 25 nmol
  - 50 nmol
  - 200 nmol
  - 1000 nmol
  - 10,000 nmol
- Purification
- Modification

Oligonucleotide Synthesis Application Outlook (Revenue, USD Million, 2014 - 2025)

PCR Primers
PCR Assays and Panels
Sequencing
DNA Microarrays
Fluorescence In Situ Hybridization (FISH)
Antisense Oligonucleotides
Other Applications

Oligonucleotide Synthesis End-use Outlook (Revenue, USD Million, 2014 - 2025)

Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies

Oligonucleotide Synthesis Regional Outlook (Revenue, USD Million, 2014 - 2025)

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
Asia Pacific
- Japan
- China
Latin America
- Brazil
Middle East and Africa (MEA)
- South Africa

About Us:Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/

Wednesday, 19 June 2019

Global Artificial Organ & Bionics Market to Reach USD 38.75 Billion By 2020

The global Artificial Organ And Bionics Market is expected to reach USD 38.75 billion by 2020 at an estimated CAGR of 9.3% from 2014 to 2020, according to a new study by Grand View Research, Inc. Increasing prevalence of acute renal failure and renal disorders due to lifestyle habits such as excessive alcohol consumption and growing geriatric population base causing a rise in organ failure rates is expected to serve this market as a high impact rendering driver. In addition, growing incidence rates of accidents is expected to boost the demand for organ transplants, thus increasing demand for artificial organ. Artificial kidney dominated the global market in 2013, with revenue estimated at over USD 12.21 billion; demand is expected grow due to the increasing chronic kidney patients. Artificial liver is the fastest growing market

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/artificial-organ-and-bionics

Further key findings from the study suggest:

Brain bionics in the medical bionics market held the largest share of revenue for the year 2013 and the market is expected to grow at an estimated CAGR of 40.0%.The presence of high unmet medical needs in neurology disease segment coupled with expensive treatment procedures is expected to drive the market for brain bionics. Exoskeleton is the fastest growing segment and is expected to grow at a CAGR of 16.0% from 2014 to 2020.

North America was the largest regional market in 2013, accounting for over 42.0% of global revenue due to the increasing population and awareness among the patients and the players.

Asia Pacific is the fastest growing market and is expected to grow at a CAGR of 11.0% from 2014 to 2020 on account of rising demand due to the improvement in healthcare facilities, medical tourism and others.Increasing income levels and healthcare expenditure is expected to interest of the players’ in the emerging markets.

Key industry participants include Abiomed Inc., Asahi Kasei Kuraray Medical Co. Ltd., Thoratec Corporation, WorldHeart Corp., Gambro AB and others.

Grand View Research has segmented the global artificial organ and bionics market on the basis of product, technology and region:

Artificial Organ Product Outlook

Artificial organs

Total artificial heart
Artificial liver
Artificial pancreas
Artificial lungs
Artificial kidney

Bionics

Cochlear implants
Exoskeletons
Cardiac bionics

Heart valves
Biological tissue valves
Mechanical valves
Transcatheter heart valves

Ventricular assist device

Bionic limbs

Bionic legs
Bionic hands

Brain bionics

Deep brain stimulators
Spinal cord stimulators
Vagus nerves stimulators

Vision bionics

Artificial Organ Technology Outlook

Mechanical bionics
Electronic bionics

Artificial Organ Regional Outlook

North America
Europe
Asia Pacific
RoW

Tuesday, 18 June 2019

Hi-Tech Medical Devices Market Segmentation and Future Scope, 2025

The global Hi-Tech Medical Devices Market size is expected to reach USD 197.87 billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 29.8% during the forecast period. Employee wellness programs along with enhanced precision, aesthetics, and durability of devices are among the primary growth stimulants for the market.

Market players are focusing on aesthetics while designing these devices as they are meant for daily wear. There are immense opportunities for players who are developing luxury watches and jewelry that have all features of smart wearables, which is certain to attract luxury spenders. New generation of consumers demand innovative luxury items with a blend of exclusivity, fashion, and connectivity, which serves as a key driver for the demand for hi-tech medical devices.

North America held a substantial share in the hi-tech medical devices market in 2017, due to high accessibility of supportive infrastructure such as hi-speed internet connection, presence of a raft of multinational companies, and increasing awareness among people. Besides, multinational companies (MNC) provide various schemes that allow users buy devices at a lesser price. Asia Pacific is anticipated to witness phenomenal growth in the coming years, owing to high unmet needs, improving healthcare infrastructure, and rising per capita expenditure. Moreover. presence of a large user base and booming economy, especially in India and China, are also bolstering the growth of the regional market.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/hi-tech-medical-devices-market

Further key findings from the report suggest:

Smart phones emerged as the largest segment owing to their integration with other devices such as smart watches and fitness trackers
Fitness trackers are expected to witness the fastest growth during the forecast period
Handheld devices dominated the market in 2017. This can be attributed to advent of innovative cameras, high speed internet connection, larger storage capacity, and fast processers
North America dominated the hi-tech medical devices market in 2017, owing to existence of various multinational companies and presence of supportive infrastructure such as hi-speed internet connection
Some of the prominent companies operating in the market are Apple; Google; Adida AG; Nike, Inc.; Samsung; Sony Corporation; Xiaomi; CAE HEALTHCARE; and Virtual-Realities Ltd.

Grand View Research has segmented the global hi-tech medical devices market on the basis of product, site, and region:

Hi-Tech Medical Devices Product Outlook (Revenue, USD Million, 2014 - 2025)

Smart phones
Tablets
Smart Watches
Fitness Trackers
Virtual Reality Sets
Others

Hi-Tech Medical Devices Site Outlook (Revenue, USD Million, 2014 - 2025)

Handheld
Headband
Strap, Clip, Bracelet
Shoe Sensors
Others

Hi-Tech Medical Devices Regional Outlook (Revenue, USD Million, 2014 - 2025)

North America

U.S.
Canada

Europe

U.K.
Germany

Asia Pacific

Japan
China

Latin America

Brazil
Mexico

Middle East & Africa

South Africa
Saudi Arabia